WASOG 2023 conference highlights
Main Article Content
Keywords
diagnosis; sarcoidosis; pulmonary fibrosis; biomarkers; GWAS; genetics; biobanks; big data; precision medicine
Abstract
The World Association of Sarcoidosis and Other Granulomatous Diseases (WASOG) 2023 conference held in Stockholm, Sweden, focused on disseminating the science and updating the interstitial lung diseases (ILDs) community with the latest science and concepts in precision medicine. This article summarizes the first four sessions of the conference that focused on disease and phenotype characterization, genetics in population cohorts, uses of biobanks and big data, epidemiology in diverse racial and ethnic groups, and data-driven applications that can be applicable to move the ILD field toward precision medicine.
References
2. Papiris SA, Georgakopoulos A, Papaioannou AI, Pianou N, Kallergi M, Kelekis NL, Gialafos H, Manali ED, Chatziioannou S: Emerging phenotypes of sarcoidosis based on 18F-FDG PET/CT: a hierarchical cluster analysis. Expert review of respiratory medicine 2020, 14(2):229-238.
3. Grutters JC: Establishing a Diagnosis of Pulmonary Sarcoidosis. Journal of Clinical Medicine 2023, 12(21):6898.
4. Levy M, Kolodziejczyk AA, Thaiss CA, Elinav E: Dysbiosis and the immune system. Nature Reviews Immunology 2017, 17(4):219-232.
5. Saint-Criq V, Lugo-Villarino G, Thomas M: Dysbiosis, malnutrition and enhanced gut-lung axis contribute to age-related respiratory diseases. Ageing research reviews 2021, 66:101235.
6. Rivera NV, Ronninger M, Shchetynsky K, Franke A, Nothen MM, Muller-Quernheim J, Schreiber S, Adrianto I, Karakaya B, van Moorsel CH et al: High-Density Genetic Mapping Identifies New Susceptibility Variants in Sarcoidosis Phenotypes and Shows Genomic-driven Phenotypic Differences. Am J Respir Crit Care Med 2016, 193(9):1008-1022.
7. Duckworth A, Gibbons MA, Allen RJ, Almond H, Beaumont RN, Wood AR, Lunnon K, Lindsay MA, Wain LV, Tyrrell J et al: Telomere length and risk of idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease: a mendelian randomisation study. The Lancet Respiratory medicine 2021, 9(3):285-294.
8. Van Dyke MV, Martyny JW, Mroz MM, Silveira LJ, Strand M, Fingerlin TE, Sato H, Newman LS, Maier LA: Risk of chronic beryllium disease by HLA-DPB1 E69 genotype and beryllium exposure in nuclear workers. Am J Respir Crit Care Med 2011, 183(12):1680-1688.
9. Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS, Poletti V, Buccioli M, Elicker BM, Jones KD et al: A multidimensional index and staging system for idiopathic pulmonary fibrosis. Annals of internal medicine 2012, 156(10):684-691.
10. van der Vis JJ, Prasse A, Renzoni EA, Stock CJW, Caliskan C, Maher TM, Bonella F, Borie R, Crestani B, Petrek M et al: MUC5B rs35705950 minor allele associates with older age and better survival in idiopathic pulmonary fibrosis. Respirology 2023, 28(5):455-464.
11. Baughman RP, Lower E: D. Geraint James Lecture: The sarcoidosis saga: what insights from the past will guide us in the future. Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG / World Association of Sarcoidosis and Other Granulomatous Disorders 2023, 40(4):e2023057.
Article Sidebar
Article Details
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
